相关实验视频

Updated: Jun 3, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

针对PI3K/mTOR:对于明显细胞卵巢癌的潜在治疗策略

Kewei Zheng¹, Guanqin Jin¹, Rui Cao²

¹Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China.

Cancer chemotherapy and pharmacology

|January 10, 2025

概括

一种PI3K/mTOR抑制剂WX390与西斯普拉丁结合,显示出对卵巢清细胞癌 (OCCC) 的协同作用. 这种组合有效地抑制瘤生长,并在OCCC模型中增强化疗敏感性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

卵巢清晰细胞癌 (OCCC) 由于其高恶性瘤,化疗耐药性和预后不佳而构成重大临床挑战.
拉巴胺 (PI3K/AKT/mTOR) 途径的酸酸3-酶/蛋白酶B/哺乳动物点与包括OCCC在内的各种癌症的进展和不良结果有关.

研究的目的:

为了研究WX390的联合治疗效果,一个双PI3K/mTOR抑制剂,和cisplatin在卵巢清细胞癌 (OCCC).
在临床前OCCC模型中阐明这种组合疗法的有效性背后的分子机制.

主要方法:

使用OCCC细胞系 (ES2,OVISE) 的体外研究和使用患者衍生异种移植 (PDX) 模型的体内实验.
评估细胞增殖,细胞亡,细胞循环动态,并通过西斑和RNA测序途径抑制.

主要成果:

WX390显著抑制了OCCC细胞增殖和诱导亡.
在PDX模型中,WX390和西斯 (CDDP) 的组合表现出协同作用,增强OCCC细胞对化疗的敏感性,并抑制瘤生长.
WX390有效地抑制了PI3K/AKT/mTOR通路,破坏了自,改变了细胞周期进展,并诱导了亡.

结论:

在临床前的OCCC模型中,WX390显示出相当大的疗效,无论是作为单一药物还是与西斯普拉丁结合使用.
这些发现为开发基于WX390的卵巢清细胞癌的治疗策略提供了强有力的理由.

关键词:

细胞灭亡 (apoptosis) 是一种死亡的过程.自自是一种自的过程.组合疗法是一种联合疗法.卵巢的透明细胞癌.核武器的扩散有针对性的治疗.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...